The company recently published the results of its safety assessment on the biotechnologically-produced 3-Fucosyllactose (3-FL) HMO.
3-FL is a highly abundant complex carbohydrate and is one of over 130 HMOs currently identified in human milk. They promote bacterial growth, especially bifidobacteria genus, in the gut, which helps improve metabolic activity, increase pathogen resistance and modulates immune responses. The antimicrobial protection and prebiotic functions of the product allow HMOs to be used in various applications, including infant formula and dietary supplements.
Using standardized testing protocols for new ingredients, the research team tested the safety of this new ingredient for early life nutrition. Researchers produced 3-FL by fermentation and then assessed for acute oral toxicity, in vitro and in vivo of genetic toxicity, and included a sub chronic rodent feeding study.
The results found that sub-chronic dietary exposure of rats to 3-FL did not produce any statistical or biologically relevant differences in growth, food intake or efficiency, clinical observations, or clinical or anatomic pathology changes. The evidence from these studies support the safe use of 3-FL produced using biotechnology as a nutritional ingredient in foods and dietary supplements.
“This is an important milestone for the launch of Care4U 3-FL, the next HMO from DuPont. A robust safety assessment has been completed for 3-FL demonstrating the safe use as a nutritional ingredient in foods,” said Ratna Mukherjea, Ph.D., technical fellow and global R&D leader for HMO. “We continue to innovate in Early Life Nutrition by providing ingredients such as HMOs and probiotics to support good nutrition in the First 1000 Days.”
HMO is one piece of DuPont’s digestive health puzzle
This latest study props up past research which suggested that commercially-produced HMOs can replicate some of the health-promoting effects of the HMOs present in human milk. In 2018, DuPont launched 2’-fucosyllactose (2’-FL) in 2018 under the name CARE4U for infant nutrition and dietary supplements.
DuPont is already a key player in probiotics, with an operation in Rochester, New York, the world’s largest probiotics fermentation plant.
The HMO market
According to Grandview Research, the global HMO market size was estimated at $19.3 million in 2019. As the industry works to manufacture a breastmilk substitute that’s as close to nature as possible, the market is expected to expand at a CAGR of 23% during the forecast period.
Grandview points to increasing concerns among consumers regarding gut health and the growing consumption of dietary supplements as reasons behind the growth.
The leading annual event for the prebiotic, probiotic and microbiota focused food and pharma industries.
As part of the Probiota Series, the event will bring together professionals from across the globe to network, connect and engage whilst learning about the hottest topics in the industry.
Join us as we connect the business and science of the microbiome May 27 – 29, 2020.
Source: Food and Chemical Toxicology
Vol 134, Dec 2019, 110818 https://doi.org/10.1016/j.fct.2019.110818
“Safety assessment of the biotechnologically produced human-identical milk oligosaccharide 3-Fucosyllactose (3-FL)”
Authors: J. Pitt et al.